{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T08:09:53Z","timestamp":1774771793234,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021729","name":"Medizinische Fakult\u00e4t der Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015135","name":"Haemonetics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015135","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Platelet reactivity (PR) in clopidogrel-treated patients undergoing percutaneous coronary syndrome (PCI)\u00a0associates with ischemic and bleeding risk. The aim was to investigate the association of PR and global hemostasis with this risk in patients with atrial fibrillation (AF) undergoing PCI. TEG was performed on day 1\u20133 after PCI. 168 patients were included. Mean age was 79 years (IQR 72\u201382).\u00a0101 (60%) patients had high platelet reactivity (HPR). HPR was not associated with the composite outcome of MACE (HR 1.23 [ CI 95% 0.43\u20133.49],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.700). 33(19.6%) patients had HPR and increased platelet\u2013fibrin clot strength and showed a trend for association with higher ischemic risk (HR 2.83 [CI 95% 0.70\u20138.06],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.078). Rates of HPR in patients with AF undergoing PCI were\u00a0high. Neither HPR nor LPR predicted ischemic or bleeding risks. Patients with HPR and increased platelet\u2013fibrin clot strength may be at higher risk for ischemic events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12265-025-10673-4","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:03:59Z","timestamp":1756307039000},"page":"1312-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-3901","authenticated-orcid":false,"given":"Diona","family":"Gjermeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Anfang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Juelch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leggewie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hesselbarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"J\u00e4ckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph B.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"10673_CR1","unstructured":"2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic [Internet]. [cited 2024 Oct 20];Available from: https:\/\/academic.oup.com\/eurheartj\/article\/44\/38\/3720\/7243210?login=false."},{"key":"10673_CR2","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1055\/s-0038-1675401","volume":"118","author":"K Steensig","year":"2018","unstructured":"Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, B\u00f8tker HE, Lip GYH, Maeng M. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western denmark heart registry. Thromb Haemost. 2018;118:2162\u201370.","journal-title":"Thromb Haemost"},{"key":"10673_CR3","first-page":"1609","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2016;18:1609\u201378.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"10673_CR4","doi-asserted-by":"crossref","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, L\u00f8chen M-L, Lumbers RT, Maesen B, M\u00f8lgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D, ESC Scientific Document Group. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45:3314\u20133414.","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"10673_CR5","doi-asserted-by":"crossref","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S, ESC Scientific Document Group. ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3415\u20133537.","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"10673_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","volume":"160","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate\u2013induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160:346\u201354.","journal-title":"Am Heart J"},{"key":"10673_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/jcm10081565","volume":"10","author":"J Gruttemeier","year":"2021","unstructured":"Gruttemeier J, Cottin Y, Yao H, De Maistre E, Maza M, Bonello L, Laine M, Resseguier N, Zeller M, Camoin-Jau L, Paganelli F. Impact of platelet reactivity in ACS patients on clinical outcomes with triple antithrombotic therapy. J Clin Med. 2021;10:1565.","journal-title":"J Clin Med"},{"key":"10673_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11239-016-1397-5","volume":"42","author":"J Rilinger","year":"2016","unstructured":"Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser JS, Zhou Q, Bode C, Moser M, Diehl P, Olivier CB. High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. J Thromb Thrombolysis. 2016;42:558\u201365.","journal-title":"J Thromb Thrombolysis"},{"key":"10673_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Kom\u00f3csi A, D\u00e9zsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann F-J, Koltowski L, Mehilli J, Huczek Z, Massberg S, Parma R, Parma Z, Lesiak M, Komosa A, Huczek Z, Koltowski L, Kowara M, Rymuza B, Klopotowski M, Malek L, Aradi D, Veress G, D\u00e9zsi AD, Merkely B, Lux \u00c1, Kiss RG, Papp J, Kov\u00e1cs A, D\u00e9zsi CA, Amer S, Ruzsa Z, R\u00f3na S, Kom\u00f3csi A, Ili R, Ungi I, Nagy F, Zweiker R, T\u00f3th-Gayor G, Huber K, Haller P, von Scheidt W, Bl\u00fcthgen A, Neumann F-J, Trenk D, Leggewie S, Kreider-Stempfle HU, Remp T, Kara K, M\u00fcgge A, Wutzler A, Fichtlscherer S, Zeiher AM, Seeger F, Hinterseer M, K\u00f6nig A, Lederle S, Jacobshagen C, Czepluch F, Maier L, Schillinger W, Sossalla S, Hummel A, Felix S, Karakas M, Sydow K, Rudolph T, Halbach M, Gori T, M\u00fcnzel T, May A, Gerstenberg C-M, Pilecky D, Rieber J, Deichstetter M, Sibbing D, Mehilli J, Gross L, K\u00e4\u00e4b S, L\u00f6w A, Orban M, Orban M, Sattler S, Deuschl S, Teupser D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747\u201357.","journal-title":"Lancet"},{"key":"10673_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/heartasia-2013-010296","volume":"5","author":"X-M Hou","year":"2013","unstructured":"Hou X-M, Han W-Z, Qiu X-B, Fang W-Y. Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography. Heart Asia. 2013;5:66\u20139.","journal-title":"Heart Asia"},{"key":"10673_CR11","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/eurheartj\/ehae296","volume":"45","author":"O Kwon","year":"2024","unstructured":"Kwon O, Ahn J-H, Koh J-S, Park Y, Hwang SJ, Tantry US, Gurbel PA, Hwang J-Y, Jeong Y-H. Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J. 2024;45:2217\u201331.","journal-title":"Eur Heart J"},{"key":"10673_CR12","doi-asserted-by":"crossref","unstructured":"Li Y, Chang H, Ni L, Xue P, Li C, Yuan L, Cui H, Yu C. Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention. Exp Ther Med [Internet]. 2019 [cited 2022 May 19];Available from: http:\/\/www.spandidos-publications.com\/10.3892\/etm.2019.7294.","DOI":"10.3892\/etm.2019.7294"},{"key":"10673_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324.","journal-title":"N Engl J Med"},{"key":"10673_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O\u2019Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961\u201372.","journal-title":"Circulation"},{"key":"10673_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005;3:692\u20134.","journal-title":"J Thromb Haemost JTH"},{"key":"10673_CR16","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet J-P, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong Y-H, Mehran R, Moliterno DJ, Neumann F-J, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521\u201337.","journal-title":"JACC Cardiovasc Interv"},{"key":"10673_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/phar.2776","volume":"43","author":"MS Buckley","year":"2023","unstructured":"Buckley MS, Benanti GE, Meckel J, Tekle LA, Gilbert B, Puebla Neira D, McNierney DA, Korkames G, Yerondopoulos M, Park A, O\u2019Hea JA, MacLaren R. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Pharmacotherapy. 2023;43:196\u2013204.","journal-title":"Pharmacotherapy"},{"key":"10673_CR18","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.3390\/jcm11144237","volume":"11","author":"D Gjermeni","year":"2022","unstructured":"Gjermeni D, Vetter H, Szab\u00f3 S, Anfang V, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, Olivier CB. Thrombelastography compared with multiple impedance aggregometry to assess high on-clopidogrel reactivity in patients with atrial fibrillation undergoing percutaneous coronary intervention. J Clin Med. 2022;11:4237.","journal-title":"J Clin Med"},{"key":"10673_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1160\/TH13-08-0643","volume":"111","author":"Y-H Jeong","year":"2014","unstructured":"Jeong Y-H, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost. 2014;111:713\u201324.","journal-title":"Thromb Haemost"},{"key":"10673_CR20","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting. J Am Coll Cardiol. 2005;46:1820\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"10673_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11239-020-02103-w","volume":"50","author":"JS Bae","year":"2020","unstructured":"Bae JS, Ahn J-H, Jang JY, Cho SY, Kang MG, Kim K-H, Park HW, Koh J-S, Park Y, Hwang S-J, Kwak CH, Hwang J-Y, Tantry US, Gurbel PA, Jeong Y-H. The impact of platelet\u2013fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. J Thromb Thrombolysis. 2020;50:969\u201381.","journal-title":"J Thromb Thrombolysis"},{"key":"10673_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/ALN.0000000000003061","volume":"132","author":"SP Myers","year":"2020","unstructured":"Myers SP, Dyer MR, Hassoune A, Brown JB, Sperry JL, Meyer MP, Rosengart MR, Neal MD. Correlation of thromboelastography with apparent rivaroxaban concentration: has point-of-care testing improved? Anesthesiology. 2020;132:280\u201390.","journal-title":"Anesthesiology"},{"key":"10673_CR23","doi-asserted-by":"crossref","unstructured":"Hesselbarth D, Gjermeni D, Szabo S, Siegel PM, Diehl P, Moser M, Bode C, Olivier CB. Time from blood draw to multiple electrode aggregometry and association with platelet reactivity. J Thromb Thrombolysis [Internet]. 2022 [cited 2022 Nov 16];Available from: https:\/\/link.springer.com\/10.1007\/s11239-022-02720-7.","DOI":"10.1007\/s11239-022-02720-7"},{"key":"10673_CR24","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","volume":"137","author":"Y-D Tang","year":"2018","unstructured":"Tang Y-D, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y, Yuan X, Ji H, Zhou Z, Liu Z, Chen J, Yuan J, Liu H, Qian J, Hu F, Shao C, Zhao H, Hua Y, Lu J. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation. 2018;137:2231\u201345.","journal-title":"Circulation"},{"key":"10673_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1160\/TH16-10-0496","volume":"117","author":"RP Kreutz","year":"2017","unstructured":"Kreutz RP, Schmeisser G, Maatman B, Schaffter A, Sinha A, Der Lohe EV, Breall JA. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention. Thromb Haemost. 2017;117:426\u20138.","journal-title":"Thromb Haemost"},{"key":"10673_CR26","unstructured":"New interest in fibrinogen as an ischemic risk factor | Journal of Thrombosis and Thrombolysis [Internet]. [cited 2024 Oct 24];Available from: https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03024-8."},{"key":"10673_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacc.2014.03.051","volume":"64","author":"W Hochholzer","year":"2014","unstructured":"Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O\u2019Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel. J Am Coll Cardiol. 2014;64:361\u20138.","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10673-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10673-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10673-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:11:49Z","timestamp":1763565109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10673-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10673"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10673-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and amendments were approved by the local ethics committee (Freiburg,Germany), privacy and security offices, and institutional review board (Ethic protocol number: 21\u20131146). The study was registered at the German register for clinical trials (DRKS00024509).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"We confirm that all participants involved in this study have provided informed consent to participate. The study was conducted in accordance with ethical guidelines, and participants were made aware of their rights, including the ability to withdraw from the study at any time without penalty. All necessary ethical approvals have been obtained for the use of informed consents and information sheets for study participants in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"We confirm that all study participants have consented to publish the result of the study. We confirm also that all authors of this manuscript have given their consent for the manuscript to be submitted for publication. Additionally, the manuscript has not been submitted elsewhere and is not under consideration for publication by any other journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"CBO reports research support from Haemonetics, Deutsche Forschungsgemeinschaft, Faculty of Medicine, Freiburg University; Else Kr\u00f6ner-Fresenius Stiftung; honoraria: Bayer Vital GmbH, Daiichi Sankyo, Ferrer, Idorsia. DT reports research support by a grant from Deutsche Herzstiftung. He received within the last 24\u00a0months consulting fees\/payment for lectures including service on speakers\u2019 bureaus by Alexion Pharma, Amgen, AstraZeneca, Atriva, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Ferrer, Pfizer and Sanofi; DG reports research support by a grant from German Research Foundation; DD received speaker\u2019s honoraria from Daiichi Sankyo, Bayer Healthcare, Boehringer Ingelheim, Pfizer, Sanofi, AOP Health, Boston Scientific, and Novartis, consulting fees from Boston Scientific and Bayer Healthcare, and was supported by the Deutsche Forschungsgemeinschaft (SFB1425 Project #422681845, SFB1366 Project # 394046768), by the Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung (DZHK), and by the Helmholtz-Institute for Translational AngioCardioScience (HI-TAC).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}